Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$1.09 - $20.4 $11,428 - $213,893
10,485 New
10,485 $13,000
Q1 2022

May 16, 2022

SELL
$1.46 - $2.45 $19,474 - $32,680
-13,339 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$2.13 - $3.46 $28,412 - $46,152
13,339 New
13,339 $31,000
Q2 2021

Aug 16, 2021

SELL
$3.8 - $4.56 $131,480 - $157,776
-34,600 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$4.33 - $6.63 $41,849 - $64,078
-9,665 Reduced 21.83%
34,600 $159,000
Q4 2020

Feb 16, 2021

BUY
$4.87 - $17.29 $129,503 - $459,775
26,592 Added 150.47%
44,265 $268,000
Q3 2020

Nov 16, 2020

BUY
$15.08 - $27.04 $71,494 - $128,196
4,741 Added 36.66%
17,673 $291,000
Q2 2020

Aug 14, 2020

BUY
$14.57 - $23.96 $188,419 - $309,850
12,932 New
12,932 $302,000
Q1 2020

May 15, 2020

SELL
$10.27 - $21.23 $440,839 - $911,297
-42,925 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$8.36 - $23.81 $133,216 - $379,412
-15,935 Reduced 27.07%
42,925 $878,000
Q3 2019

Nov 14, 2019

BUY
$9.83 - $14.82 $410,461 - $618,823
41,756 Added 244.13%
58,860 $579,000
Q2 2019

Aug 14, 2019

BUY
$12.9 - $20.8 $220,641 - $355,763
17,104 New
17,104 $231,000
Q1 2019

May 15, 2019

SELL
$17.7 - $24.93 $464,306 - $653,963
-26,232 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$19.05 - $36.45 $348,900 - $667,581
18,315 Added 231.34%
26,232 $593,000
Q3 2018

Nov 14, 2018

BUY
$34.41 - $44.23 $93,698 - $120,438
2,723 Added 52.43%
7,917 $294,000
Q2 2018

Aug 14, 2018

BUY
$39.21 - $50.29 $203,656 - $261,206
5,194 New
5,194 $204,000
Q1 2018

May 15, 2018

SELL
$41.7 - $64.16 $346,110 - $532,528
-8,300 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$28.58 - $49.91 $237,214 - $414,253
8,300
8,300 $376,000

Others Institutions Holding ASMB

# of Institutions
1
Shares Held
16.3K
Call Options Held
0
Put Options Held
0

About ASSEMBLY BIOSCIENCES, INC.


  • Ticker ASMB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,436,900
  • Market Cap $737M
  • Description
  • Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...
More about ASMB
Track This Portfolio

Track Squarepoint Ops LLC Portfolio

Follow Squarepoint Ops LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.